Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

COVID-19: Omicron Transmissibility, Severity, and Vaccine Effectiveness

Transmissibility, disease severity, and vaccine effectiveness are different with the SARS-CoV-2 omicron variant compared with the ancestral virus and prior variants. Hear expert faculty discuss what we know about omicron.
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Released: February 22, 2022

In this episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, discusses what is known about the SARS-CoV-2 omicron variant, including:

  • Transmissibility and infectiousness
    • Immune evasion
  • Disease severity
    • Risks of hospitalization and death
  • Vaccine effectiveness  
    • 2- vs 3-dose vaccine effectiveness
    • T-cell response

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.

Information on this Educational Activity

Faculty

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia

Sharon R. Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.

Program Medium

This program has been made available online.

Related Content

Prof. Sharon R. Lewin: expert insights on remdesivir for nonhospitalized adult and pediatric patients with COVID-19, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Prof. Sharon R. Lewin discusses ivermectin and the evolution of monoclonal antibody treatments during omicron, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Megan Coffee, MD, PhD, discusses the newest data on SARS-CoV-2 diagnostics from CROI 2022 and elsewhere, from Clinical Care Options (CCO)

Megan Coffee, MD, PhD (DPhil) Released: June 2, 2022

Frequently asked questions and answers: evolving data on COVID-19 epidemiology, prevention, and treatment, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Renslow Sherer, MD Released: June 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings